Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals (NASDAQ: REGN ) stock is on the rise Thursday after the company released its latest data on Dupixent. Dupixent is a drug candidate for treating adults on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data

Sanofi

Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with "smoker's lung," leading SNY and REGN stocks to rocket. The post Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' appeared first on Investor's Business Daily.

Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'

Coinbase

First Republic

Here were some of the more active stocks in premarket trading on Thursday, a day after sharp losses on Wall Street after the Federal Reserve's latest interest rate hike:

Coinbase' stock tumbles on SEC warning, while First Republic and Regeneron shares rally, and other stocks on the move

Shares of Regeneron Pharmaceuticals Inc. REGN, -1.11% rallied about 7% in premarket trading on Thursday after the company said a pivotal Phase 3 clinical trial showed that Dupixent reduced exacerbations in people with uncontrolled chronic obstructive pulmonary disease (COPD), compared with placebo. U.S.-listed shares of Sanofi SNY, +0.47% , which co-developed Dupixent, were up about 6%.

Regeneron, Sanofi say Dupixent works in COPD

Dupixent ® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial

First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo

Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial

Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.

Regeneron (REGN) Gets Label Extension for Cholesterol Drug

MCBC Hlds

Vitru Limited

Atkore International Group

Diodes

Immersion

With the market still digesting the tremors of the banking sector fallout, investors may want to consider compelling value stocks to buy, even those trading near their 52-week highs. True, investors often wax poetic about buying low and selling high.

7 Value Stocks Worth Buying at These 52-Week Highs

Dupixent ® (dupilumab) a pproved by European Commission as f irst and o nly t argeted m edicine for c hildren as y oung as s ix m onths o ld with s evere a topic d ermatitis

Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis

Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

Dupixent ® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of m oderate-to-severe a topic h and and f oot d ermatitis

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.

Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?

Halozyme Therapeutics

Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday. The post Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme appeared first on Investor's Business Daily.

Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme

Sarepta Therapeutics

Check out these 2 biotech stocks in the stock market today.

2 Biotech Stocks To Watch In March 2022

2 Biotech Stocks To Watch In March 2023

Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday. The post Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme appeared first on Investor's Business Daily.

Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Barclays Global Healthcare Conference March 15, 2023 9:00 AM ET Company Participants Ryan Crowe - Vice President of Investor Relations Robert Landry - Chief Financial Officer Conference Call Participants Carter Gould - Barclays Carter Gould [Technical difficulty] -- Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst, here at Barclays.

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays Global Healthcare Conference (Transcript)

$250,000 top award goes to Neel Moudgal in the nation's oldest and most prestigious science and math competition for high school seniors TARRYTOWN, N.Y. and WASHINGTON, March 14, 2023 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.  and Society for Science  (the Society) announced that Neel Moudgal, 17, of Saline, Mich.

Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 9:20 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Neil Stahl - Executive Vice President, Research and Development Jamie Orengo - Vice President, Allergy and Immunity Research Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great. For joining us, I always have to remember to give that pause.

Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 33rd Annual Healthcare Conference

Eylea, the company's top-selling blockbuster, isn't going away soon.

Regeneron Borrows From Big Pharma Playbook

Beam Therapeutics

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Novartis

Verve Therapeutics

Vertex Pharmaceuticals

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

Dupixent ® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review

More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines

Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Cowen 43rd Annual Health Care Conference March 6, 2023 12:50 PM ET Company Participants Marion McCourt - EVP of Commercial Ryan Crowe - Vice President & Head of IR Conference Call Participants Tyler Van Buren - Cowen Tyler Van Buren Good afternoon, everyone. I'm Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

News for Regeneron Pharmaceuticals Stock (REGN)